PRNewswire covers the news of welcoming Kennon Broadhurst to the BioAgilytix team, bringing with him over 26 years of experience in sales, marketing and product commercialization experience.
BioAgilytix has received its Certificate of Accreditation for high complexity testing in the diagnostic immunology specialty from the Commission on Office Laboratory Accreditation (COLA) for its U.S. facility in Durham, North Carolina.
Dr. Fjording will be based at BioAgilytix’s European laboratory in Hamburg, Germany and will provide scientific and regulatory oversight to BioAgilytix’s team in the development and implementation of strategies for bioanalytical assay development and regulated assay validation.
The new name is reflective of BioAgilytix’s plan, which was set forth following its acquisition of Boston-based Cambridge Biomedical in late 2019, to fully integrate Cambridge Biomedical’s clinical and diagnostic testing capabilities into BioAgilytix’s global service offerings.
BioAgilytix supplies its assay expertise to describe the appropriate analytical assays needed to determine and ensure that biosimilar critical quality parameters are on track.
In this role, Dr. Briscoe will provide scientific and regulatory oversight to BioAgilytix’s global teams with strategic guidance in line with emerging scientific developments.
In this role, Dr. Nicholson will oversee bioanalytical operations and scientific team development across BioAgilytix’s laboratories in both the USA and Europe, with particular focus leading the organization’s Gene and Cell Therapy bioanalytical services.
In this role, Dr. Horling will lead Operations, Finance, HR, and Facilities for BioAgilytix’s European business and its laboratory located in Hamburg, Germany.
Dr. McNally brings with him an extensive background in bioanalytical assay development and program leadership working for almost 20 years in the pharmaceutical and biotechnology industry.
Mr. Marasco will provide strategic direction to BioAgilytix’s global business development and marketing functions / teams to further expand worldwide adoption of the company’s premier bioanalytical services.
Platforms
Services